Clinical Trials · NCT06097390
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 121
- Start date
- Sep 2023
- Locations
- 1 site, Canada
- Primary endpoint
- Adjusted AUC0-24h,sema; adjusted area under the semaglutide plasma concentration-time curve